CJC-1295 vs FOXO4-DRI
Side-by-Side Comparison
| Attribute | Cjc 1295 | Foxo4 Dri |
|---|---|---|
| Category | Growth Hormone Secretagogue | Senolytic / Anti-Aging |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Senescent cells survive because FOXO4 protein binds to p53 in the nucleus, sequestering it and preventing p53 from triggering apoptosis. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Preclinical. No human clinical trials. Animal studies in aged mice (Baar et al., Cell 2017). |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No human safety data exists; Mouse studies used doses of 5 mg/kg via intraperitoneal injection |
| Route | Subcutaneous | Subcutaneous (extrapolated from IP injection in mice) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | No established human dose. Mouse studies used 5 mg/kg IP every 3 days for 3 weeks. |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Every 3 days for treatment course (mouse protocol extrapolation) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | N/A |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Extended (D-amino acid configuration resists proteolysis) |
Overview
CJC-1295 and FOXO4-DRI are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
FOXO4-DRI — Mechanism & Evidence
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional "zombie cells" that accumulate in tissues and drive chronic inflammation, tissue dysfunction, and age-related disease. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing them to undergo apoptosis while leaving healthy cells unaffected. It is one of the first peptide-based senolytics and has generated significant interest in the longevity research community.
Key claims: Selectively eliminates senescent cells; Reverses age-related vascular decline; Restores testosterone in aged males.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
FOXO4-DRI is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
FOXO4-DRI: No human safety data exists Mouse studies used doses of 5 mg/kg via intraperitoneal injection Transient weight loss and reduced food intake observed in treated mice
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.